Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

E-Poster Display

1283P - Tepotinib in patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Julien Mazieres

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

J. Mazieres1, P.K. Paik2, E. Felip3, R. Veillon4, H. Sakai5, A.B. Cortot6, S. Viteri7, M.C. Garassino8, J.P. Van Meerbeeck9, J. Raskin9, M. Thomas10, M. Morise11, B.C. Cho12, P. Conte13, R. Bruns14, T. Demuth15, K.M. Schumacher15, X. Le16

Author affiliations

  • 1 Chu De Toulouse, Institut Universitaire du Cancer, 30030 - Toulouse/FR
  • 2 Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York/US
  • 3 Department Of Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona/ES
  • 4 Chu Bordeaux, service des maladies respiratoires, Bordeaux/FR
  • 5 Department Of Thoracic Oncology, Saitama Cancer Center, Saitama/JP
  • 6 Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 – UMR-S 1277 - Canther, F-59000, Lille/FR
  • 7 Dr Rosell Oncology Institute, Dexeus University Hospital, QuironSalud Group, Barcelona/ES
  • 8 Department Of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 9 Department Of Pulmonology And Thoracic Oncology, Antwerp University Hospital (UZA), Edegem/BE
  • 10 Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), The German Center for Lung Research (DZL), Heidelberg/DE
  • 11 Department Of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya/JP
  • 12 Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR
  • 13 Department Of Surgery, Oncology And Gastroenterology, University of Padova and Oncologia Medica 2, Istituto Oncologico Veneto, I.R.C.C.S., Padova/IT
  • 14 Department Of Biostatistics, Merck KGaA, Darmstadt/DE
  • 15 Global Clinical Development, Merck KGaA, Darmstadt/DE
  • 16 Department Of Thoracic Head And Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 1283P

Background

The multi-cohort phase II VISION study investigates tepotinib in pts with NSCLC with MET alterations, and is the largest study of pts with METex14 skipping detected by liquid (L+) or tissue (T+) biopsy. Here we report efficacy outcomes in the overall intention-to-treat population.

Methods

Pts with advanced, EGFR/ALK wild-type, METex14 skipping NSCLC received oral tepotinib 500 mg once daily. Evaluable pts for objective response rate (ORR) had ≥2 post-baseline assessments or discontinuation for any reason. Primary endpoint: ORR by independent review committee (IRC). Secondary endpoints: investigator-assessed (INV) ORR, duration of response (DOR), progression-free survival (PFS), and safety. Objective responses were confirmed by two scans ≥4 weeks apart. Subgroup analyses were preplanned.

Results

By data cut-off (01 Jan 2020), Cohort A had enrolled 152 pts: 52% male, median age 73 years (range 41–94), 43% non-smokers, 55% had received prior treatment for advanced/ metastatic disease. Overall ORR (95% CI) in evaluable pts (n=146; 95 L+ and 84 T+) was 44.5% (36.3, 53.0) by IRC and 54.8% (46.4, 63.0) by INV. ORR was consistent across subgroups, supporting robustness of efficacy (Table). Median DOR (95% CI) in L+ pts was 9.9 months (7.2, not estimable [ne]) by IRC and 14.0 months (7.2, ne) by INV, and in T+ pts was 12.4 months (9.7, ne) by IRC and 16.4 months (9.7, ne) by INV. Median PFS in L+ pts was 8.5 months (6.7, 10.9) by IRC and 8.5 months (5.8, 11.0) by INV, and in T+ pts was 11.0 months (7.8, 17.1) by IRC and 12.2 months (6.8, 19.6) by INV. Grade ≥3 treatment-related adverse events (TRAEs) were reported by 27.6% of pts; 17 (11.2%) discontinued due to TRAEs, mostly peripheral edema (4.6%). The safety profile was similar across subgroups. Table: 1283P

ORR, % (95% CI) IRC INV
L+ 47.4 (37.0, 57.9) 54.7 (44.2, 65.0)
T+ 45.2 (34.3, 56.5) 58.3 (47.1, 69.0)
Gender
M 46.1 (34.5, 57.9) 52.6 (40.8, 64.2)
F 42.9 (31.1, 55.3) 57.1 (44.7, 68.9)
Age
<75 50.0 (38.6, 61.4) 56.3 (44.7, 67.3)
≥75 37.9 (26.2, 50.7) 53.0 (40.3, 65.4)
Race
Caucasian 43.1 (33.4, 53.3) 52.0 (41.8, 62.0)
Asian 47.4 (31.0, 64.2) 60.5 (43.4, 76.0)
ECOG PS
0 59.5 (42.1, 75.2) 56.8 (39.5, 72.9)
1 39.4 (30.2, 49.3) 54.1 (44.3, 63.7)
Smoker
Y 51.3 (39.6, 63.0) 51.3 (39.6, 63.0)
N 35.5 (23.7, 48.7) 56.5 (43.3, 69.0)
Therapy line
1 44.6 (32.3, 57.5) 52.3 (39.5, 64.9)
≥2 44.4 (33.4, 55.9) 56.8(45.3, 67.8)
Prior platinum-based therapy
Y 48.6 (36.7, 60.7) 58.3 (46.1, 69.8)
N 42.3 (30.6, 54.6) 50.7 (38.6, 62.8)

Conclusions

Tepotinib has durable clinical activity across subgroups and manageable toxicity in the largest study of pts with METex14 skipping NSCLC identified by L+ or T+.

Clinical trial identification

NCT02864992.

Editorial acknowledgement

Medical writing assistance (funded by Merck KGaA, Darmstadt, Germany) was provided by Syneos Health, London, UK.

Legal entity responsible for the study

Merck KGaA, Darmstadt, Germany.

Funding

Merck KGaA, Darmstadt, Germany.

Disclosure

J. Mazieres: Advisory/Consultancy: Roche; Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Novartis. P.K. Paik: Advisory/Consultancy: AbbVie; Advisory/Consultancy: BMS; Advisory/Consultancy: Calithera; Advisory/Consultancy, Research grant/Funding (institution): Celgene; Advisory/Consultancy: Lilly; Advisory/Consultancy: Takeda; Research grant/Funding (self), Research grant/Funding (institution): EMD Serono. E. Felip: Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS; Advisory/Consultancy: Guardant Health; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda; Advisory/Consultancy: AbbVie; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy: Merck KGaA; Advisory/Consultancy, Speaker Bureau/Expert testimony: Merck Sharp & Dohme; Advisory/Consultancy: Janssen; Advisory/Consultancy: Samsung; Speaker Bureau/Expert testimony: Medscape; Speaker Bureau/Expert testimony: prIME Oncology; Speaker Bureau/Expert testimony: Touchtime; Research grant/Funding (self): Fundación Merck Salud; Research grant/Funding (self): Grant for Oncology Innovation (GOI); Officer/Board of Directors: Grifols (Independent Member). R. Veillon: Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Novartis; Speaker Bureau/Expert testimony, Research grant/Funding (self): BMS; Speaker Bureau/Expert testimony, Research grant/Funding (self): Roche; Research grant/Funding (self): Takeda; Research grant/Funding (self): AbbVie; Research grant/Funding (self): Merck. H. Sakai: Speaker Bureau/Expert testimony: BMS; Speaker Bureau/Expert testimony: Ono Pharmaceutical; Speaker Bureau/Expert testimony: MSD K.K.; Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony: Chugui Pharma; Speaker Bureau/Expert testimony: Taiho Pharmaceutical; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Merck KGaA. A.B. Cortot: Research grant/Funding (self): Merck KGaA; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Takeda. S. Viteri: Advisory/Consultancy: AbbVie; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Speaker Bureau/Expert testimony: MSD; Travel/Accommodation/Expenses: OSE Pharma; Travel/Accommodation/Expenses: Merck. M.C. Garassino: Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Sanofi; Speaker Bureau/Expert testimony: Otsuka Pharma; Speaker Bureau/Expert testimony: Incyte; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony: Takeda; Advisory/Consultancy, Speaker Bureau/Expert testimony, steering committee: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, steering committee: AstraZeneca; Honoraria (self), Advisory/Consultancy, honoraria for speaker: Takeda. J.P. Van Meerbeeck: Advisory/Consultancy: Amgen; Travel/Accommodation/Expenses: BMS. J. Raskin: Advisory/Consultancy: Pfizer; Advisory/Consultancy: Lilly; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: BMS; Travel/Accommodation/Expenses: Roche. M. Thomas: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): MSD; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): Lilly; Honoraria (self), Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): Chugai; Honoraria (self), Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): Celgene; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses, Honoraria – Scientific Meetings (self): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Takeda. M. Morise: Speaker Bureau/Expert testimony: Chugai; Speaker Bureau/Expert testimony: MSD; Speaker Bureau/Expert testimony: ONO; Speaker Bureau/Expert testimony: AstraZeneca. B.C. Cho: Advisory/Consultancy, Research grant/Funding (self): Novartis; Research grant/Funding (self): Bayer; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): MOGAM Institute; Research grant/Funding (self): Dong-A ST; Research grant/Funding (self), Licensing/Royalties: Champions Oncology; Advisory/Consultancy, Research grant/Funding (self): Janssen; Advisory/Consultancy, Research grant/Funding (self): Yuhan; Advisory/Consultancy, Research grant/Funding (self): Ono; Research grant/Funding (self): Dizal Pharma; Advisory/Consultancy, Research grant/Funding (self): MSD; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Roche; Advisory/Consultancy: BMS; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Takeda; Shareholder/Stockholder/Stock options: TheraCanVac Inc; Shareholder/Stockholder/Stock options: Gencurix Inc; Shareholder/Stockholder/Stock options: Bridgebio Therapeutics. P. Conte: Speaker Bureau/Expert testimony, Research grant/Funding (self), Travel/Accommodation/Expenses: Novartis; Speaker Bureau/Expert testimony, Research grant/Funding (self): Roche; Research grant/Funding (self): Merck KGaA; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Celgene; Travel/Accommodation/Expenses: Tesaro. R. Bruns: Full/Part-time employment: Merck KGaA, Darmstadt, Germany. T. Demuth: Full/Part-time employment: Merck KGaA, Darmstadt, Germany. K.M. Schumacher: Full/Part-time employment: Merck KGaA, Darmstadt, Germany. X. Le: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: EMD Serono; Research grant/Funding (self): Eli Lilly; Research grant/Funding (self): Boehringer Ingelheim.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.